{"nctId":"NCT01542788","briefTitle":"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon","startDateStruct":{"date":"2012-03"},"conditions":["Chronic Hepatitis C"],"count":278,"armGroups":[{"label":"SOF+RBV","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to match SOF","Drug: Placebo to match RBV"]}],"interventions":[{"name":"SOF","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":[]},{"name":"Placebo to match SOF","otherNames":[]},{"name":"Placebo to match RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infection with HCV genotype 2 or 3\n* Cirrhosis determination\n* Subject meets one of the following classifications:\n\n  1. IFN unwilling\n  2. IFN ineligible\n  3. IFN intolerant\n* Screening laboratory values within defined thresholds\n* Subject has not been treated with any investigational drug or device within 30 days of the Screening visit\n* Use of highly effective contraception methods if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase\n* Pregnant or nursing female or male with pregnant female partner\n* Current or prior history of clinical hepatic decompensation\n* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol\n* Excessive alcohol ingestion or significant drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving SVR12","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ, ie, \\< 25 IU/mL) 12 weeks after cessation of therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug","description":"The number of subjects experiencing adverse events leading to permanent discontinuation of study drug was summarized. Adverse events may or may not have been related to study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR4","description":"SVR4 was defined as HCV RNA \\< LLOQ 4 weeks after cessation of therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR24","description":"SVR24 was defined as HCV RNA \\< LLOQ 24 weeks after cessation of therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Breakthrough","description":"Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Relapse","description":"Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":207},"commonTop":["Fatigue","Nausea","Headache","Insomnia","Pruritus"]}}}